Severe Asthma Research Program
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- Milton S. Hershey Medical Center
- Enrollment
- 1100
- Locations
- 8
- Primary Endpoint
- Pulmonary function test results
- Status
- Active, not recruiting
- Last Updated
- 8 months ago
Overview
Brief Summary
The mission of the SARP is to improve the understanding of severe asthma through integrated study of its clinical and biological features and to evaluate their changes over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.
Detailed Description
The mission of the SARP is to improve the understanding of severe asthma to develop better treatments. The SARP will gain a better understanding of asthma and its endotypes, in children and adults, by defining the disease at the molecular and cellular levels in the context of the temporal phenotypic expression of the disease. To this end, the SARP investigators will utilize both mechanistic and evoked phenotype approaches to: 1) characterize developmental molecular, cellular and physiologic phenotypes in children and adults with mild to severe asthma, and 2) to further elucidate the evolving pathobiology and pathogenesis of severe asthma and its sub-phenotypes and 3) compare these features over time. This approach involves a shared longitudinal protocol conducted across all participating centers which includes common information on all SARP participants. Additionally, the SARP investigators have each identified mechanistic research questions to be included in the shared longitudinal protocol. Together, these longitudinal and mechanistic approaches will enable prediction of phenotype stability/fluctuation and pharmacologic responses and identification of novel, disease-modifying targets for treatment.
Investigators
dave mauger
Professor of Public Health Sciences
Milton S. Hershey Medical Center
Eligibility Criteria
Inclusion Criteria
- •Physician diagnosis of asthma,
- •Age 6 years and older
- •Evidence of historical reversibility, including either:
- •FEV1 bronchodilator reversibility ≥ 12%, or
- •Airway hyperresponsiveness reflected by a methacholine PC20 ≤16 mg/mL.
Exclusion Criteria
- •Pregnancy during the characterization phase,
- •Current smoking,
- •Smoking history \> 10 pack years if ≥30 years of age, or smoking history \> 5 pack years if \<30 years of age (Note: if a subject has a smoking history, no smoking within the past year),
- •Other chronic pulmonary disorders associated with asthma-like symptoms, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways,
- •History of premature birth before 35 weeks gestation,
- •Unwillingness to receive an intramuscular triamcinolone acetonide injection,
- •Evidence that the participant or family may be unreliable or poorly adherent to their asthma treatment or study procedures,
- •Planning to relocate from the clinical center area before study completion,
- •Any other criteria that place the subject at unnecessary risk according to the judgment of the Principal Investigator and/or attending physician(s) of record, or
- •Currently participating in an investigational drug trial for asthma therapies.
Outcomes
Primary Outcomes
Pulmonary function test results
Time Frame: 36 months after enrollment
Pulmonary function test results include forced expiratory volume in one second (FEV1) and forced vital capacity (FVC).
Secondary Outcomes
- Frequency of severe asthma exacerbations(36 months after enrollment)